Artificial intelligence (AI) is transforming various industries as a major investing theme in 2025. The technology's ability to automate complex workflows and enhance productivity is seen as a game-changer for the next generation of innovation.Perhaps the most promising AI application is its potential to revolutionize medicine by accelerating the drug discovery process to deliver more effective therapies. Several biotechnology companies are embracing these cutting-edge capabilities to unlock new growth oppo ...

Consumers Can Apply Today for a Chance to be Featured in an Upcoming Campaign by Natrelle® and Share Their Personal Stories. Natrelle® is the #1 Selected Breast Implant by Leading U.S. Physicians* Offering the Largest Range of Options For Every Curve, Every Shape, For Every BODY. IRVINE, Calif., Feb. 6, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced a nationwide open casting call in search of the next Faces of Natrelle®, encouraging women who have experienced breast rec ...

AbbVie (ABBV) announced strong fourth-quarter 2024 results last week, beating estimates for both earnings and sales. While earnings of $2.16 per share declined around 22% year over year, sales rose 6.1% on an operational basis, mainly driven by robust sales of its immunology medicines, Skyrizi and Rinvoq. While sales of Skyrizi rose 57.9% on an operational basis, Rinvoq sales were up 47.1%. AbbVie’s other key drugs, Venclexta and Vraylar, coupled with significant contributions from newer drugs Ubrelvy, Elah ...

POLAND - 2024/11/17: In this photo illustration, the AbbVie company logo is seen displayed on a ... [+] smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty Images AbbVie (NYSE: ABBV) recently released its Q4 results, with revenues and earnings comfortably above the street estimates. It reported sales of $15.1 billion and adjusted earnings of $2.16 per share, compared to the consensus estimates of $14.8 billion and $2.11, respectivel ...

Join iREIT on Alpha today to get the most in-depth research that includes REITs, mREITs, Preferreds, BDCs, MLPs, ETFs, and other income alternatives. 438 testimonials and most are 5 stars. Nothing to lose with our FREE 2-week trial .If you ask someone who owns a construction company in the Sunbelt, odds are he or she is upbeat, supported by economic re-shoring and a lot ofAnalyst’s Disclosure: I/we have a beneficial long position in the shares of NSC, UNP, CP, ABBV either through stock ownership, options, o ...

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.AbbVie Inc. (NYSE: ABBV ) stock has surged by over 7% in trading so far today, as the company released its Q4 earnings and full-year 2024 earnings, and provided guidance fo ...

I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up to Growth Stock Forum.He leads the investing group Growth Stock Forum which features: a model portfolio of 15-2 ...

AbbVie Inc. (ABBV) reported fourth-quarter 2024 adjusted earnings of $2.16 per share, which beat the Zacks Consensus Estimate of $2.13. The reported earnings also exceeded the company’s guidance of $2.06-$2.10 issued earlier this month. Earnings declined around 23% year over year due to increased IPR&D expenses incurred during the quarter.See the Zacks Earnings Calendar to stay ahead of market-making news.ABBV’s revenues of $15.10 billion beat the Zacks Consensus Estimate of $14.87 billion. Sales rose 5.6% ...

Shares of AbbVie (ABBV 6.95%) were jumping 7.1% higher as of 11:10 a.m. ET on Friday after rising as much as 9.2% earlier in the day. The nice gain stemmed from the big drugmaker's 2024 fourth-quarter update on Friday morning.AbbVie reported Q4 net revenue of $15.1 billion, up 5.6% and higher than the average estimate of $14.87 billion of analysts surveyed by Zacks Investment Research. The company posted a loss in Q4 of $0.02 per share based on generally accepted accounting principles (GAAP). However, it re ...

Today’s pre-market activity is positive, with futures in the green across major indexes: the Dow is +110 points at this hour, with the S&P 500 +26 and the Nasdaq leading the way, +158 points. The small-cap Russell 2000 is +5. Each of these indexes has been trading +1% or higher through the past five trading days, and between +4% (Nasdaq) and a robust +7% (Dow) off its January lows.PCE Numbers In-Line for DecemberThe Fed’s preferred gauge for inflation is the Personal Consumption Expenditures (PCE) report, w ...